Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson’s disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers, as well as on developing treatment for pancreatic and other cancers. Oncodesign Precision Medicine Société anonyme was founded in 1995 and is based in Dijon, France.
Metrics to compare | ALOPM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALOPMPeersSector | |
---|---|---|---|---|
P/E Ratio | 1.3x | −2.2x | −0.7x | |
PEG Ratio | - | 0.07 | 0.00 | |
Price/Book | 0.8x | 1.4x | 2.6x | |
Price / LTM Sales | 4.8x | 7.0x | 3.4x | |
Upside (Analyst Target) | 325.5% | 139.2% | 39.2% | |
Fair Value Upside | Unlock | 16.9% | 6.1% | Unlock |